Skip to main content
Top

15-09-2023 | Type 2 Diabetes | News

Young-onset type 2 diabetes diagnosis linked to shortened life expectancy

Author: Laura Cowen

print
PRINT
insite
SEARCH

medwireNews: Research by the Emerging Risk Factors Collaboration shows that being diagnosed with type 2 diabetes at a younger age is associated with shorter life expectancy, with 3 to 4 years lost for every decade of earlier diagnosis.

The data show that “high priority should be given to developing and implementing interventions that prevent or delay the onset of the condition, especially as its prevalence among younger age groups is increasing globally,” write Emanuele Di Angelantonio (University of Cambridge, UK) and collaborators in The Lancet Diabetes & Endocrinology.

They add: “The evidence also highlights the need for intensive treatment of risk factors for premature mortality among young adults diagnosed with diabetes.”

The findings are based on an analysis of information from two large-scale data sources (Emerging Risk Factors Collaboration and UK Biobank) that cover multiple prospective cohorts from 19 high-income countries. A total of 1,515,718 participants (mean age 55 years, 54% women) with a median 12.5 years (23.1 million person–years) of follow-up were included.

Di Angelantonio and co-authors report that they observed “a steep linear dose–response association between earlier age at diagnosis of diabetes and higher risk of all-cause mortality.”

After adjustment for age and sex, the team found that individuals diagnosed with type 2 diabetes at 30–39 years of age were a significant 2.69 times more likely to die of any cause during follow-up than those without diabetes. Diabetes diagnosis at age 40–49 years was associated with a significant 2.26-fold increased risk for all-cause mortality, while the risk increases were a significant 1.84-, 1.57-, and 1.39-fold for participants diagnosed at 50–59 years, 60–69 years, and 70 years and older, respectively.

Additional adjustment for risk factors such as BMI, systolic blood pressure, and total cholesterol had minimal impact on the results, but the researchers note the associations were “attenuated substantially” after further adjustment for fasting glucose or glycated hemoglobin levels.

Di Angelantonio then estimated how many years of life people with diabetes might lose depending on their age at diagnosis. Using death rates from the USA, they calculated that an individual with diabetes surviving to 50 years would die an average of 14 years earlier than someone without diabetes if the diabetes diagnosis occurred at 30 years of age. If they were diagnosed age 40 years, they would die 10 years earlier than a person without diabetes, and 6 years earlier if diagnosed age 50 years.

Of note, the estimates were slightly higher for women (16, 11, and 7 years, respectively) than for men (14, 9, and 5 years, respectively).

Around 30–45% of the reduction in life expectancy was due to deaths from cardiovascular disease, with the remaining proportion largely attributed to respiratory, neurologic, or infectious disease, and external causes.

The results were similar when the researchers used European mortality data, with deaths occurring at an average of 13, 9, and 5 years earlier when individuals were diagnosed with diabetes at 30, 40, and 50 years of age, respectively.

In an accompanying editorial, Bruce Duncan and Maria Inês Schmidt, both from the Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil, say the data are “of concern” and suggest that young-onset diabetes, typically defined as onset before age 40 years, “can now also be characterised as a condition that significantly reduces life expectancy.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group

Lancet Diabetes Endocrinol 2023; doi:10.1016/S2213-8587(23)00223-1
Lancet Diabetes Endocrinol 2023; doi:10.1016/S2213-8587(23)00255-3

print
PRINT

Related topics

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

A 28-year-old male patient (188 cm, 72 kg) presents to the central emergency department with dorsal pain after returning from a trip to East Asia. He reports feeling a bit tired and listless without classic signs of infection. In the clinical examination, apart from an approximately fist-sized, deeply situated, sturdy and non-displaceable bulging of the abdominal wall sinistrally paraumbilically, a slight enlargement of the left testis with pain upon palpation is noticeable. What is your first suspicion, and what are your first diagnostic steps?

The 46-year-old male patient has been showing various signs of inflammation for 6–8 weeks: Sore throat, canker sores, joint pain and febrile rhinitis. There is an unintended weight loss of 2–3 kg. Physical examination reveals findings that are inconspicuous for the patient’s age. How do you proceed now?

A 76-year-old, overweight female patient with anaemia and type II diabetes noted by her family doctor presents with fatigue, forgetfulness and yellowish pallor in a neglected state. Moreover, she shows an increasingly unsteady gait. How do you proceed?

A 56-year-old man presents with concentration problems, dorsal pain, fatigue and a marked increase in urination. His family history is positive for bronchial carcinoma. Physical examination reveals tenderness upon percussion in the lumbar spine. How do you proceed?

Navigating the Treatment of Renal Cell Carcinoma

Insights on the Current Treatment Landscape and Managing Patient Health

In recent years, tremendous efforts have been made in the medical treatment of metastatic renal cell carcinoma (mRCC), with Immune-Oncological combinations standing as the current standard of care in the first-line setting of mRCC. 

In these podcasts, expert authors discuss the current treatment landscape for these new therapies and discuss what should be taken into account when choosing the most appropriate treatment for their patients so as to balance oncological outcomes, adverse events and quality of life.

Supported by an unrestricted educational grant from Eisai Europe Limited.

Listen now